Abstract
While vulvar lichen sclerosus (VLS) causes intense pruritus, associated risks of mood disorders and prescription patterns and impact of concurrent sexual dysfunction are unknown. We queried TriNetX Diamond Network between 2009 and 2022, conducting three comparisons after propensity-score matching for demographics and relevant comorbidities: (1) women with lichen sclerosus (LS) sparing the vulva vs. women with VLS; (2) VLS patients who received treatment within 6 months of diagnosis vs. patients who did not and (3) VLS patients with vs. without sexual dysfunction. Outcomes included new depressive episodes, anxiety disorder, major depressive disorder (MDD), and prescriptions of antidepressants or benzodiazepines. After matching, VLS was associated with increased depressive episode [risk ratio (RR) 1.39], anxiety disorder (RR 1.93), and MDD (RR 2.00) diagnoses compared to LS sparing the vulva. Next, VLS treatment was associated with decreased risk of depressive episode (RR 0.60) and anxiety disorder (RR 0.72). Finally, concurrent sexual dysfunction was associated with increased benzodiazepine (RR 3.50), vaginal estrogen (RR 6.20), antipruritic agents (RR 3.90), and topical anti-inflammatory (RR 2.61) prescriptions. In conclusion, vulvar involvement is associated with increased risk of antidepressant and benzodiazepine prescriptions, and diagnosis of depressive episode, anxiety disorder, or MDD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data used in this study are from the TriNetX deidentified database, which is available from TriNetX, LLC (https://trinetx.com/). Third-party restrictions affect availability of these data that prevent it from being made publicly available or redistributed. Researchers can access the TriNetX database through TriNetX, LLC.
References
Kraus CN. Vulvar Lichen Sclerosus. JAMA Dermatol. 2022;158:1088. https://doi.org/10.1001/jamadermatol.2022.0359.
Van de Nieuwenhof HP, Meeuwis KAP, Nieboer TE, Vergeer MCM, Massuger LFAG, De Hullu JA. The effect of vulvar lichen sclerosus on quality of life and sexual functioning. J Psychosom Obstet Gynaecol. 2010;31:279–84. https://doi.org/10.3109/0167482X.2010.507890.
Rivera S, Flood A, Dykstra C, Herbenick D, DeMaria AL. Genital Self-Image, Sexual Function, and Quality of Life Among Individuals with Vulvar and Non-Vulvar Inflammatory Dermatoses. Arch Sex Behav. Published online July 28, (2022). https://doi.org/10.1007/s10508-022-02353-0.
Sadownik LA, Koert E, Maher C, Smith KB. A Qualitative Exploration of Women’s Experiences of Living With Chronic Vulvar Dermatoses. J Sex Med. 2020;17:1740–50. https://doi.org/10.1016/j.jsxm.2020.06.016.
Brauer M, van Lunsen R, Burger M, Laan E. Motives for Vulvar Surgery of Women with Lichen Sclerosus. J Sex Med. 2015;12:2462–73. https://doi.org/10.1111/jsm.13052.
Chmel R, Nováčková M, Fait T, Zámečník L, Krejčová L, Pastor Z. Clitoral Phimosis: Effects on Female Sexual Function and Surgical Treatment Outcomes. J Sex Med. 2019;16:257–66. https://doi.org/10.1016/j.jsxm.2018.12.012.
Haefner HK, Aldrich NZ, Dalton VK, Gagné HM, Marcus SB, Patel DA, et al. The impact of vulvar lichen sclerosus on sexual dysfunction. J Womens Health 2002. 2014;23:765–70. https://doi.org/10.1089/jwh.2014.4805.
Corazza M, Borghi A, Gafà R, Ghirardi C, Ferretti S. Risk of vulvar carcinoma in women affected with lichen sclerosus: results of a cohort study. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2019;17:1069–71. https://doi.org/10.1111/ddg.13961.
Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol. 2015;151:1061–7. https://doi.org/10.1001/jamadermatol.2015.0643.
Corazza M, Borghi A, Minghetti S, Toni G, Virgili A. Clobetasol propionate vs. mometasone furoate in 1-year proactive maintenance therapy of vulvar lichen sclerosus: results from a comparative trial. J Eur Acad Dermatol Venereol JEADV. 2016;30:956–61. https://doi.org/10.1111/jdv.13166.
Virgili A, Minghetti S, Borghi A, Corazza M. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. Br J Dermatol. 2013;168:1316–24. https://doi.org/10.1111/bjd.12273.
Lee A, Fischer G. Diagnosis and treatment of vulvar lichen sclerosus: an update for dermatologists. Am J Clin Dermatol. 2018;19:695–706. https://doi.org/10.1007/s40257-018-0364-7.
Day T, Otton G, Dennerstein G, Tran H, Scurry J. Erosive Lichen sclerosus—a clinicopathologic subtype. J Low Genit Tract Dis. 2021;25:255–60. https://doi.org/10.1097/LGT.0000000000000607.
Mazdisnian F, Degregorio F, Mazdisnian F, Palmieri A. Intralesional injection of triamcinolone in the treatment of lichen sclerosus. J Reprod Med. 1999;44:332–4.
Lutfey KE, Link CL, Rosen RC, Wiegel M, McKinlay JB. Prevalence and correlates of sexual activity and function in women: results from the Boston Area Community Health (BACH) Survey. Arch Sex Behav. 2009;38:514–27. https://doi.org/10.1007/s10508-007-9290-0.
Cheng H, Oakley A, Conaglen JV, Conaglen HM. Quality of life and sexual distress in women with erosive vulvovaginal lichen planus. J Low Genit Tract Dis. 2017;21:145–9. https://doi.org/10.1097/LGT.0000000000000282.
Skrzypulec V, Olejek A, Drosdzol A, Nowosielski K, Kozak-Darmas I, Wloch S. Sexual functions and depressive symptoms after photodynamic therapy for vulvar lichen sclerosus in postmenopausal women from the Upper Silesian Region of Poland. J Sex Med. 2009;6:3395–400. https://doi.org/10.1111/j.1743-6109.2009.01505.x.
Burrows LJ, Creasey A, Goldstein AT. The treatment of vulvar lichen sclerosus and female sexual dysfunction. J Sex Med. 2011;8:219–22. https://doi.org/10.1111/j.1743-6109.2010.02077.x.
ICD-10-CM. Accessed August 26, (2023). https://icd10cmtool.cdc.gov/.
Rights (OCR) O for C. The HIPAA Privacy Rule. HHS.gov. Published May 7, 2008. Accessed October 8, (2023). https://www.hhs.gov/hipaa/for-professionals/privacy/index.html.
Fan R, Leasure AC, Maisha FI, Little AJ, Cohen JM. Depression and anxiety in patients with lichen sclerosus. JAMA Dermatol. 2022;158:953–4. https://doi.org/10.1001/jamadermatol.2022.1964.
Govind V, Mitchell L, Tolson H, Barela K, Casey J, Goldstein A. 089 exploring comorbidity of anxiety and depression in lichen sclerosus. J Sex Med. 2019;16:S34. https://doi.org/10.1016/j.jsxm.2019.03.530.
Timur S, Sahin NH. The prevalence of depression symptoms and influencing factors among perimenopausal and postmenopausal women. Menopause N Y N. 2010;17:545–51. https://doi.org/10.1097/gme.0b013e3181cf8997.
Jung SJ, Shin A, Kang D. Hormone-related factors and post-menopausal onset depression: results from KNHANES (2010-2012). J Affect Disord. 2015;175:176–83. https://doi.org/10.1016/j.jad.2014.12.061.
Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev. 2011;(12):CD008240. https://doi.org/10.1002/14651858.CD008240.pub2.
Hosseinzadeh Zoroufchi B, Doustmohammadi H, Mokhtari T, Abdollahpour A. Benzodiazepines related sexual dysfunctions: A critical review on pharmacology and mechanism of action. Rev Int Androl. 2021;19:62–68. https://doi.org/10.1016/j.androl.2019.08.003.
Margesson LJ. Practice gaps: Practice gaps “down there”: failures in education, physical examination, recognition, diagnosis, therapy, follow-up care, and cancer surveillance in lichen sclerosus. JAMA Dermatol. 2013;149:1203. https://doi.org/10.1001/jamadermatol.2013.4895.
Bleeker MCG, Visser PJ, Overbeek LIH, van Beurden M, Berkhof J. Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2016;25:1224–30. https://doi.org/10.1158/1055-9965.EPI-16-0019.
Cooper SM, Wojnarowska F. Influence of treatment of erosive lichen planus of the vulva on its prognosis. Arch Dermatol. 2006;142:289–94. https://doi.org/10.1001/archderm.142.3.289.
Author information
Authors and Affiliations
Contributions
UEC and TK analyzed the data and UEC, RCN and EW wrote the article. PA, TK, JK, and MC provided substantial edits and guidance. All authors revised the article and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval
This study was exempt from IRB approval as only anonymized data was used.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Choi, U.E., Nicholson, R.C., Agrawal, P. et al. Involvement of vulva in lichen sclerosus increases the risk of antidepressant and benzodiazepine prescriptions for psychiatric disorder diagnoses. Int J Impot Res (2023). https://doi.org/10.1038/s41443-023-00793-3
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41443-023-00793-3